# Patent

## Title
Receptor binding polypeptides

## Abstract

Isolated polypeptides containing fragments of SARS CoV S protein and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating infection with a coronavirus are also disclosed.

## Background
RELATED APPLICATION
This application claims priority to U.S. Provisional Application Ser. No. 60/535,641, filed on Jan. 9, 2004, the content of which is incorporated by reference in its entirety.


Please insert official copy (copy 2) of sequence listing on the compact disc which has the file name US 11/033,455txt, contains 204 KB, and created on Jun. 10, 2005, is hereby incorporated by reference in to the specification following the Abstract
BACKGROUND
Virus is the cause of various disorders. For example, members of the coronavirus family cause hepatitis in mice, gastroenteritis in pigs, and respiratory infections in birds and humans. Among the more than 30 strains isolated so far, three or four infect humans. The severe acute respiratory syndrome (SARS), a newly found infectious disease, is associated with a novel coronavirus. This life-threatening respiratory coronavirus touched off worldwide outbreaks in 2003. Vaccines and drugs against SARS coronavirus (CoV) are being vigorously sought. Nevertheless, the progress has been rather slow due to safety concerns.
SUMMARY
This invention is based, at least in part, on the discovery of receptor binding domains of the SARS CoV Spike (S) protein. Genomic sequences of a number of SARS CoV strains can be found in GenBank. GenBank Accession No. AY278741 (SEQ ID NO: 1) represents the genomic sequence of the SARS CoV Urbani strain, which contains an open reading frame encoding a polypeptide that is 7,073 amino acid residues (aa.) in length (SEQ ID NO: 2). The nucleic acid encoding the S protein of this strain corresponds to nucleotides (nt) 21,492-25,259 of GenBank Accession No. AY278741. Listed below are the nucleic acid and amino acid sequences of the S protein:








21492             atgtttatt ttcttattat ttcttactct cactagtggt agtgaccttg



 


21541 accggtgcac cacttttgat gatgttcaag ctcctaatta cactcaacat acttcatcta


 


21601 tgaggggggt ttactatcct gatgaaattt ttagatcaga cactctttat ttaactcagg


 


21661 atttatttct tccattttat tctaatgtta cagggtttca tactattaat catacgtttg


 


21721 gcaaccctgt catacctttt aaggatggta tttattttgc tgccacagag aaatcaaatg


 


21781 ttgtccgtgg ttgggttttt ggttctacca tgaacaacaa gtcacagtcg gtgattatta


 


21841 ttaacaattc tactaatgtt gttatacgag catgtaactt tgaattgtgt gacaaccctt


 


21901 tctttgctgt ttctaaaccc atgggtacac agacacatac tatgatattc gataatgcat


 


21961 ttaattgcac tttcgagtac atatctgatg ccttttcgct tgatgtttca gaaaagtcag


 


22021 gtaattttaa acacttacga gagtttgtgt ttaaaaataa agatgggttt ctctatgttt


 


22081 ataagggcta tcaacctata gatgtagttc gtgatctacc ttctggtttt aacactttga


 


22141 aacctatttt taagttgcct cttggtatta acattacaaa ttttagagcc attcttacag


 


22201 ccttttcacc tgctcaagac atttggggca cgtcagctgc agcctatttt gttggctatt


 


22261 taaagccaac tacatttatg ctcaagtatg atgaaaatgg tacaatcaca gatgctgttg


 


22321 attgttctca aaatccactt gctgaactca aatgctctgt taagagcttt gagattgaca


 


22381 aaggaattta ccagacctct aatttcaggg ttgttccctc aggagatgtt gtgagattcc


 


22441 ctaatattac aaacttgtgt ccttttggag aggtttttaa tgctactaaa ttcccttctg


 


22501 tctatgcatg ggagagaaaa aaaatttcta attgtgttgc tgattactct gtgctctaca


 


22561 actcaacatt tttttcaacc tttaagtgct atggcgtttc tgccactaag ttgaatgatc


 


22621 tttgcttctc caatgtctat gcagattctt ttgtagtcaa gggagatgat gtaagacaaa


 


22681 tagcgccagg acaaactggt gttattgctg attataatta taaattgcca gatgatttca


 


22741 tgggttgtgt ccttgcttgg aatactagga acattgatgc tacttcaact ggtaattata


 


22801 attataaata taggtatctt agacatggca agcttaggcc ctttgagaga gacatatcta


 


22861 atgtgccttt ctcccctgat ggcaaacctt gcaccccacc tgctcttaat tgttattggc


 


22921 cattaaatga ttatggtttt tacaccacta ctggcattgg ctaccaacct tacagagttg


 


22981 tagtactttc ttttgaactt ttaaatgcac cggccacggt ttgtggacca aaattatcca


 


23041 ctgaccttat taagaaccag tgtgtcaatt ttaattttaa tggactcact ggtactggtg


 


23101 tgttaactcc ttcttcaaag agatttcaac catttcaaca atttggccgt gatgtttctg


 


23161 atttcactga ttccgttcga gatcctaaaa catctgaaat attagacatt tcaccttgct


 


23221 cttttggggg tgtaagtgta attacacctg gaacaaatgc ttcatctgaa gttgctgttc


 


23281 tatatcaaga tgttaactgc actgatgttt ctacagcaat tcatgcagat caactcacac


 


23341 cagcttggcg catatattct actggaaaca atgtattcca gactcaagca ggctgtctta


 


23401 taggagctga gcatgtcgac acttcttatg agtgcgacat tcctattgga gctggcattt


 


23461 gtgctagtta ccatacagtt tctttattac gtagtactag ccaaaaatct attgtggctt


 


23521 atactatgtc tttaggtgct gatagttcaa ttgcttactc taataacacc attgctatac


 


23581 ctactaactt ttcaattagc attactacag aagtaatgcc tgtttctatg gctaaaacct


 


23641 ccgtagattg taatatgtac atctgcggag attctactga atgtgctaat ttgcttctcc


 


23701 aatatggtag cttttgcaca caactaaatc gtgcactctc aggtattgct gctgaacagg


 


23761 atcgcaacac acgtgaagtg ttcgctcaag tcaaacaaat gtacaaaacc ccaactttga


 


23821 aatattttgg tggttttaat ttttcacaaa tattacctga ccctctaaag ccaactaaga


 


23881 ggtcttttat tgaggacttg ctctttaata aggtgacact cgctgatgct ggcttcatga


 


23941 agcaatatgg cgaatgccta ggtgatatta atgctagaga tctcatttgt gcgcagaagt


 


24001 tcaatggact tacagtgttg ccacctctgc tcactgatga tatgattgct gcctacactg


 


24061 ctgctctagt tagtggtact gccactgctg gatggacatt tggtgctggc gctgctcttc


 


24121 aaataccttt tgctatgcaa atggcatata ggttcaatgg cattggagtt acccaaaatg


 


24181 ttctctatga gaaccaaaaa caaatcgcca accaatttaa caaggcgatt agtcaaattc


 


24241 aagaatcact tacaacaaca tcaactgcat tgggcaagct gcaagacgtt gttaaccaga


 


24301 atgctcaagc attaaacaca cttgttaaac aacttagctc taattttggt gcaatttcaa


 


24361 gtgtgctaaa tgatatcctt tcgcgacttg ataaagtcga ggcggaggta caaattgaca


 


24421 ggttaattac aggcagactt caaagccttc aaacctatgt aacacaacaa ctaatcaggg


 


24481 ctgctgaaat cagggcttct gctaatcttg ctgctactaa aatgtctgag tgtgttcttg


 


24541 gacaatcaaa aagagttgac ttttgtggaa agggctacca ccttatgtcc ttcccacaag


 


24601 cagccccgca tggtgttgtc ttcctacatg tcacgtatgt gccatcccag gagaggaact


 


24661 tcaccacagc gccagcaatt tgtcatgaag gcaaagcata cttccctcgt gaaggtgttt


 


24721 ttgtgtttaa tggcacttct tggtttatta cacagaggaa cttcttttct ccacaaataa


 


24781 ttactacaga caatacattt gtctcaggaa attgtgatgt cgttattggc atcattaaca


 


24841 acacagttta tgatcctctg caacctgagc tcgactcatt caaagaagag ctggacaagt


 


24901 acttcaaaaa tcatacatca ccagatgttg atcttggcga catttcaggc attaacgctt


 


24961 ctgtcgtcaa cattcaaaaa gaaattgacc gcctcaatga ggtcgctaaa aatttaaatg


 


25021 aatcactcat tgaccttcaa gaattgggaa aatatgagca atatattaaa tggccttggt


 


25081 atgtttggct cggcttcatt gctggactaa ttgccatcgt catggttaca atcttgcttt


 


25141 gttgcatgac tagttgttgc agttgcctca agggtgcatg ctcttgtggt tcttgctgca


 


25201 agtttgatga ggatgactct gagccagttc tcaagggtgt caaattacat tacacataa


 


25259 (SEQ ID NO:3)


 


  MFIFLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSD


 


  TLYLTQDLFLPFYSNVTGFHTINHTFGNPVIPFKDGIYFAATEKSNVVRG


 


  WVFGSTMNNKSQSVIIINNSTNVVIRACNFELCDNPFFAVSKPMGTQTHTM


 


  IFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKNKDGGLYVYKGYQP


 


  IDVVRDLPSGFNTLKPIFKLPLGINITNFRAILTAFSPAQDIWGTSAAAYF


 


  VGYLKPTTFMLKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSN


 


  FRVVPSGDVVRFPNITNLCPFGEVFNATKFPSVYAWERKKISNCVADYSVL


 


  YNSTFFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVI


 


  ADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDI


 


  SNVPFSPDGKPCTPPALNCYWPLNDYGFYTTTGIGYQPYRVVVLSFELLN


 


  APATVCGPKLSTDLIKNQCVNFNFNGLTGTGVLTPSSKRFQPFQQFGRDV


 


  SDFTDSVRDPKTSEILDISPCAFGGVSVITPGTNASSEVAVLYQDVNCTD


 


  VSTAIHADQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPIGAGI


 


  CASYHTVSLLRSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTE


 


  VMPVSMAKTSVDCNMYICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDR


 


  NTREVFAQVKQMYKTPTLKYFGGFNFSQILPDPLKPTKRSFIEDLLFNKVT


 


  LADAGFMKQYGECLGDINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALV


 


  SGTATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNK


 


  AISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDI


 


  LSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSE


 


  CVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPSQERNFTTAPAIC


 


  HEGKAYFPREGVFVFNGTSWFITQRNFFSPQIITTDNTFVSGNCDVVIGII


 


  NNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEI


 


  DRLNEVAKNLNESLIDLQELGKYEQYIKWPWYVWLGFIAGLIAIVMVTILLC


 


  CMTSCCSCLKGACSCGSCCKFDEDDSEPVLKGVKLHYT


(SEQ ID NO:4; the two underlines segments represent two receptor binding domains.)






One aspect of the invention features an isolated polypeptide containing SEQ ID NO: 4 or an immunogenic fragment derived from SEQ ID NO: 4. The immunogenic fragment is at least 10 amino acid residues in length, i.e., any number between 10 and 1255 (the length of SEQ ID NO: 4), inclusive. Examples of such an immunogenic fragment include the domains listed below:













Corresponding aa.




position within


Domain Name
SEQ ID NO: 4
SEQ ID NO







Receptor binding domain 1
 80-227
SEQ ID NO: 6


(RBD1)


Receptor binding domain 2
 284-735
SEQ ID NO: 8


(RBD2)


S1
  1-333
SEQ ID NO: 18


S2
 334-666
SEQ ID NO: 20


S3
 667-1000
SEQ ID NO: 22


RBD2-consensus (RBD2-C)
 434-467
SEQ ID NO: 24


RBD-55
 564-613
SEQ ID NO: 26


Transmembrane domain (TM)
1128-1255
SEQ ID NO: 28









Examples also include the fusions of two or more of the above-listed domains, e.g., RBD1-(Gly)8-TM (SEQ ID NO: 10), RBD2-(Gly)8-TM (SEQ ID NO: 12), RBD1-(Gly)8-RBD2 (SEQ ID NO: 14), and RBD1-(Gly)8-RBD2-(Gly)8-TM (SEQ ID NO: 16). In these fusions, different S protein fragments are joined by a linker of 8 glycines. Additional examples include those listed in Table 2 shown in Example 6 below. Preferably, the polypeptide of this invention contains SEQ ID NO: 24 or 26. In one embodiment, the polypeptide is a glycoprotein containing a polysaccharide, e.g., a polysaccharide from S. pneumococcal. In another embodiment, the polypeptide is a fusion protein including a heterologous polypeptide that contains an Fc portion of an immunoglobin, e.g., an IgG. Preferably, the immunoglobin is IgG1, and more preferably, a human IgG1. The fusion protein can also include a heterologous polypeptide that contains a surface portion of a protein of a pathogen, such as the HA or NA of an influenza virus.

An “isolated polypeptide” refers to a polypeptide substantially free from naturally associated molecules, i.e., it is at least 75% (i.e., any number between 75% and 100%, inclusive) pure by dry weight. Purity can be measured by any appropriate standard method, for example, by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis. An isolated polypeptide of the invention can be purified from a natural source, produced by recombinant DNA techniques, or by chemical methods. A “heterologous” protein or nucleic acid is one that originates from a foreign species, or, if from the same species, is substantially modified from its original form.
The invention also features an isolated nucleic acid that contains a sequence encoding one of the above-mentioned polypeptides. Examples of the sequence include (1) those encoding S, RBD1, RBD2, S1, S2, S3, RBD-2C, RBD-55, and TM, which, respectively, correspond to nt. 21492-25259, 21729-22172, 22341-23696, 21492-22490, 22491-23489, 23490-24491, 22791-22892, 23181-23330, and 24873-25256 of GenBank Accession No. AY278741 (SEQ ID NOs: 3, 5, 7, 17, 19, 21, 23, 25, and 27, respectively)
Listed below are exemplary sequences that encode fusion proteins RBD1-(Gly)8-TM, RBD2-(Gly)8-TM, RBD1-(Gly)8-RBD2, and RBD1-(Gly)8-RBD2-(Gly)8-TM (SEQ ID NOs: 9, 11, 13, and 15, respectively; linkers shown in the upper case):








SEQ ID NO:9



      catacgtttg gcaaccctgt catacctttt aaggatggta tttattttgc tgccacagag


 


      aaatcaaatg ttgtccgtgg ttgggttttt ggttctacca tgaacaacaa gtcacagtcg


 


      gtgattatta ttaacaattc tactaatgtt gttatacgag catgtaactt tgaattgtgt


 


      gacaaccctt tctttgctgt ttctaaaccc atgggtacac agacacatac tatgatattc


 


      gataatgcat ttaattgcac tttcgagtac atatctgatg ccttttcgct tgatgtttca


 


      gaaaagtcag gtaattttaa acacttacga gagtttgtgt ttaaaaataa agatgggttt


 


      ctctatgttt ataagggcta tcaacctata gatgtagttc gtgatctacc ttctggtttt


 


      aacactttga aacctatttt taagttgcct cttggtatta acattacaaa ttttagagcc


 


      GAATTCGGGG GCGGGGGTGG AGGTGGTGGC tcatt      caaagaagag ctggacaagt


 


      acttcaaaaa tcatacatca ccagatgttg atcttggcga catttcaggc attaacgctt


 


      ctgtcgtcaa cattcaaaaa gaaattgacc gcctcaatga ggtcgctaaa aatttaaatg


 


      aatcactcat tgaccttcaa gaattgggaa aatatgagca atatattaaa tggccttggt


 


      atgtttggct cggcttcatt gctggactaa ttgccatcgt catggttaca atcttgcttt


 


      gttgcatgac tagttgttgc agttgcctca agggtgcatg ctcttgtggt tcttgctgca


 


      agtttgatga ggatgactct gagccagttc tcaagggtgt caaattacat tacaca


 


SEQ ID NO:11


      gagattgaca aaggaattta ccagacctct aatttcaggg ttgttccctc aggagatgtt


 


      gtgagattcc ctaatattac aaacttgtgt ccttttggag aggtttttaa tgctactaaa


 


      ttcccttctg tctatgcatg ggagagaaaa aaaatttcta attgtgttgc tgattactct


 


      gtgctctaca actcaacatt tttttcaacc tttaagtgct atggcgtttc tgccactaag


 


      ttgaatgatc tttgcttctc caatgtctat gcagattctt ttgtagtcaa gggagatgat


 


      gtaagacaaa tagcgccagg acaaactggt gttattgctg attataatta taaattgcca


 


      gatgatttca tgggttgtgt ccttgcttgg aatactagga acattgatgc tacttcaact


 


      ggtaattata attataaata taggtatctt agacatggca agcttaggcc ctttgagaga


 


      gacatatcta atgtgccttt ctcccctgat ggcaaacctt gcaccccacc tgctcttaat


 


      tgttattggc cattaaatga ttatggtttt tacaccacta ctggcattgg ctaccaacct


 


      tacagagttg tagtactttc ttttgaactt ttaaatgcac cggccacggt ttgtggacca


 


      aaattatcca ctgaccttat taagaaccag tgtgtcaatt ttaattttaa tggactcact


 


      ggtactggtg tgttaactcc ttcttcaaag agatttcaac catttcaaca atttggccgt


 


      gatgtttctg atttcactga ttccgttcga gatcctaaaa catctgaaat attagacatt


 


      tcaccttgct cttttggggg tgtaagtgta attacacctg gaacaaatgc ttcatctgaa


 


      gttgctgttc tatatcaaga tgttaactgc actgatgttt ctacagcaat tcatgcagat


 


      caactcacac cagcttggcg catatattct actggaaaca atgtattcca gactcaagca


 


      ggctgtctta taggagctga gcatgtcgac acttcttatg agtgcgacat tcctattgga


 


      gctggcattt gtgctagtta ccatacagtt tctttattac gtagtactag ccaaaaatct


 


      attgtggctt atactatgtc tttaggtgct gatagttcaa ttgcttactc taataacacc


 


      attgctatac ctactaactt ttcaattagc attactacag aagtaatgcc tgtttctatg


 


      gctaaaacct ccgtagattg taatatgtac atctgcggag attctactga atgtgctaat


 


      ttgcttctcc aatatggGCG GCCGCCTGGG GGCGGGGGTG GAGGTGGTGG Ctcatt


 


      caaagaagag ctggacaagt acttcaaaaa tcatacatca ccagatgttg atcttggcga


 


      catttcaggc attaacgctt ctgtcgtcaa cattcaaaaa gaaattgacc gcctcaatga


 


      ggtcgctaaa aatttaaatg aatcactcat tgaccttcaa gaattgggaa aatatgagca


 


      atatattaaa tggccttggt atgtttggct cggcttcatt gctggactaa ttgccatcgt


 


      catggttaca atcttgcttt gttgcatgac tagttgttgc agttgcctca agggtgcatg


 


      ctcttgtggt tcttgctgca agtttgatga ggatgactct gagccagttc tcaagggtgt


 


      caaattacat tacaca


 


SEQ ID NO:13


      catacgtttg gcaaccctgt catacctttt aaggatggta tttattttgc tgccacagag


 


      aaatcaaatg ttgtccgtgg ttgggttttt ggttctacca tgaacaacaa gtcacagtcg


 


      gtgattatta ttaacaattc tactaatgtt gttatacgag catgtaactt tgaattgtgt


 


      gacaaccctt tctttgctgt ttctaaaccc atgggtacac agacacatac tatgatattc


 


      gataatgcat ttaattgcac tttcgagtac atatctgatg ccttttcgct tgatgtttca


 


      gaaaagtcag gtaattttaa acacttacga gagtttgtgt ttaaaaataa agatgggttt


 


      ctctatgttt ataagggcta tcaacctata gatgtagttc gtgatctacc ttctggtttt


 


      aacactttga aacctatttt taagttgcct cttggtatta acattacaaa ttttagagcc


 


      GAATTCGGGG GCGGGGGTGG AGGTGGTGGC gagattgaca aaggaattta ccagacctct


 


      aatttcaggg ttgttccctc aggagatgtt gtgagattcc ctaatattac aaacttgtgt


 


      ccttttggag aggtttttaa tgctactaaa ttcccttctg tctatgcatg ggagagaaaa


 


      aaaatttcta attgtgttgc tgattactct gtgctctaca actcaacatt tttttcaacc


 


      tttaagtgct atggcgtttc tgccactaag ttgaatgatc tttgcttctc caatgtctat


 


      gcagattctt ttgtagtcaa gggagatgat gtaagacaaa tagcgccagg acaaactggt


 


      gttattgctg attataatta taaattgcca gatgatttca tgggttgtgt ccttgcttgg


 


      aatactagga acattgatgc tacttcaact ggtaattata attataaata taggtatctt


 


      agacatggca agcttaggcc ctttgagaga gacatatcta atgtgccttt ctcccctgat


 


      ggcaaacctt gcaccccacc tgctcttaat tgttattggc cattaaatga ttatggtttt


 


      tacaccacta ctggcattgg ctaccaacct tacagagttg tagtactttc ttttgaactt


 


      ttaaatgcac cggccacggt ttgtggacca aaattatcca ctgaccttat taagaaccag


 


      tgtgtcaatt ttaattttaa tggactcact ggtactggtg tgttaactcc ttcttcaaag


 


      agatttcaac catttcaaca atttggccgt gatgtttctg atttcactga ttccgttcga


 


      gatcctaaaa catctgaaat attagacatt tcaccttgct cttttggggg tgtaagtgta


 


      attacacctg gaacaaatgc ttcatctgaa gttgctgttc tatatcaaga tgttaactgc


 


      actgatgttt ctacagcaat tcatgcagat caactcacac cagcttggcg catatattct


 


      actggaaaca atgtattcca gactcaagca ggctgtctta taggagctga gcatgtcgac


 


      acttcttatg agtgcgacat tcctattgga gctggcattt gtgctagtta ccatacagtt


 


      tctttattac gtagtactag ccaaaaatct attgtggctt atactatgtc tttaggtgct


 


      gatagttcaa ttgcttactc taataacacc attgctatac ctactaactt ttcaattagc


 


      attactacag aagtaatgcc tgtttctatg gctaaaacct ccgtagattg taatatgtac


 


      atctgcggag attctactga atgtgctaat ttgcttctcc aatatgg


 


SEQ ID NO:15


      catacgtttg gcaaccctgt catacctttt aaggatggta tttattttgc tgccacagag


 


      aaatcaaatg ttgtccgtgg ttgggttttt ggttctacca tgaacaacaa gtcacagtcg


 


      gtgattatta ttaacaattc tactaatgtt gttatacgag catgtaactt tgaattgtgt


 


      gacaaccctt tctttgctgt ttctaaaccc atgggtacac agacacatac tatgatattc


 


      gataatgcat ttaattgcac tttcgagtac atatctgatg ccttttcgct tgatgtttca


 


      gaaaagtcag gtaattttaa acacttacga gagtttgtgt ttaaaaataa agatgggttt


 


      ctctatgttt ataagggcta tcaacctata gatgtagttc gtgatctacc ttctggtttt


 


      aacactttga aacctatttt taagttgcct cttggtatta acattacaaa ttttagagcc


 


      GAATTCGGGG GCGGGGGTGG AGGTGGTGGC gagattgaca aaggaattta ccagacctct


 


      aatttcaggg ttgttccctc aggagatgtt gtgagattcc ctaatattac aaacttgtgt


 


      ccttttggag aggtttttaa tgctactaaa ttcccttctg tctatgcatg ggagagaaaa


 


      aaaatttcta attgtgttgc tgattactct gtgctctaca actcaacatt tttttcaacc


 


      tttaagtgct atggcgtttc tgccactaag ttgaatgatc tttgcttctc caatgtctat


 


      gcagattctt ttgtagtcaa gggagatgat gtaagacaaa tagcgccagg acaaactggt


 


      gttattgctg attataatta taaattgcca gatgatttca tgggttgtgt ccttgcttgg


 


      aatactagga acattgatgc tacttcaact ggtaattata attataaata taggtatctt


 


      agacatggca agcttaggcc ctttgagaga gacatatcta atgtgccttt ctcccctgat


 


      ggcaaacctt gcaccccacc tgctcttaat tgttattggc cattaaatga ttatggtttt


 


      tacaccacta ctggcattgg ctaccaacct tacagagttg tagtactttc ttttgaactt


 


      ttaaatgcac cggccacggt ttgtggacca aaattatcca ctgaccttat taagaaccag


 


      tgtgtcaatt ttaattttaa tggactcact ggtactggtg tgttaactcc ttcttcaaag


 


      agatttcaac catttcaaca atttggccgt gatgtttctg atttcactga ttccgttcga


 


      gatcctaaaa catctgaaat attagacatt tcaccttgct cttttggggg tgtaagtgta


 


      attacacctg gaacaaatgc ttcatctgaa gttgctgttc tatatcaaga tgttaactgc


 


      actgatgttt ctacagcaat tcatgcagat caactcacac cagcttggcg catatattct


 


      actggaaaca atgtattcca gactcaagca ggctgtctta taggagctga gcatgtcgac


 


      acttcttatg agtgcgacat tcctattgga gctggcattt gtgctagtta ccatacagtt


 


      tctttattac gtagtactag ccaaaaatct attgtggctt atactatgtc tttaggtgct


 


      gatagttcaa ttgcttactc taataacacc attgctatac ctactaactt ttcaattagc


 


      attactacag aagtaatgcc tgtttctatg gctaaaacct ccgtagattg taatatgtac


 


      atctgcggag attctactga atgtgctaat ttgcttctcc aatatggGCG GCCGCCTGGG


 


      GGCGGGGGTG GAGGTGGTGG Ctcatt     caaagaagag ctggacaagt acttcaaaaa


 


      tcatacatca ccagatgttg atcttggcga catttcaggc attaacgctt ctgtcgtcaa


 


      cattcaaaaa gaaattgacc gcctcaatga ggtcgctaaa aatttaaatg aatcactcat


 


      tgaccttcaa gaattgggaa aatatgagca atatattaaa tggccttggt atgtttggct


 


      cggcttcatt gctggactaa ttgccatcgt catggttaca atcttgcttt gttgcatgac


 


      tagttgttgc agttgcctca agggtgcatg ctcttgtggt tcttgctgca agtttgatga


 


      ggatgactct gagccagttc tcaagggtgt caaattacat tacaca






Additional examples of the nucleic acid of this invention include nucleic acids encoding the peptides listed in Table 2. In a preferred embodiment, the nucleic acid contains SEQ ID NO: 23 or 25.

A “nucleic acid” refers to a DNA molecule (e.g., a cDNA or genomic DNA), an RNA molecule (e.g., an mRNA), or a DNA or RNA analog. A DNA or RNA analog can be synthesized from nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA. An “isolated nucleic acid” is a nucleic acid the structure of which is not identical to that of any naturally occurring nucleic acid or to that of any fragment of a naturally occurring genomic nucleic acid. The term therefore covers, for example, (a) a DNA which has the sequence of part of a naturally occurring genomic DNA molecule but is not flanked by both of the coding sequences that flank that part of the molecule in the genome of the organism in which it naturally occurs; (b) a nucleic acid incorporated into a vector or into the genomic DNA of a prokaryote or eukaryote in a manner such that the resulting molecule is not identical to any naturally occurring vector or genomic DNA; (c) a separate molecule such as a cDNA, a genomic fragment, a fragment produced by polymerase chain reaction (PCR), or a restriction fragment; and (d) a recombinant nucleotide sequence that is part of a hybrid gene, i.e., a gene encoding a fusion protein. The nucleic acid described above can be used to express the polypeptide of this invention. For this purpose, one can operatively linked the nucleic acid to suitable regulatory sequences to generate an expression vector.
A “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. The vector can be capable of autonomous replication or integrate into a host DNA. Examples of the vector include a plasmid, cosmid, or viral vector. The vector of this invention includes a nucleic acid in a form suitable for expression of the nucleic acid in a host cell. Preferably the vector includes one or more regulatory sequences operatively linked to the nucleic acid sequence to be expressed. A “regulatory sequence” includes promoters, enhancers, and other expression control elements (e.g., polyadenylation signals). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence, as well as tissue-specific regulatory and/or inducible sequences. The design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like. The expression vector can be introduced into host cells to produce the polypeptide of this invention. Also within the scope of this invention is a host cell that contains the above-described nucleic acid. Examples include E. coli cells, insect cells (e.g., using baculovirus expression vectors), yeast cells, or mammalian cells. See e.g., Goeddel, (1990) Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. To produce a polypeptide of this invention, one can culture a host cell in a medium under conditions permitting expression of the polypeptide encoded by a nucleic acid of this invention, and purify the polypeptide from the cultured cell or the medium of the cell. Alternatively, the nucleic acid of this invention can be transcribed and translated in vitro, for example, using T7 promoter regulatory sequences and T7 polymerase.
A polypeptide and a nucleic acid of this invention can be used to induce an immune response (i.e., the production of specific antibodies) in a subject against a coronavirus by administering to the subject an effective amount of the polypeptide or nucleic acid encoding the polypeptide. They also can be used to generate specific antibodies that bind specifically to a polypeptide having the sequence of SEQ ID NO: 4 or its fragment. More specifically, one can generate the antibodies by administering to a non-human animal the polypeptide or nucleic acid. Thus, within the scope of this invention is a composition containing the afore-mentioned polypeptide or nucleic acid; and a pharmaceutically acceptable carrier. The composition can be used to generate the antibodies. One can purify the antibodies from the subject or the non-human animal and generate monoclonal antibodies by standard techniques.
One can use the just-described antibodies to diagnose an infection with a coronavirus, e.g., SARS-CoV, in a subject by determining the presence of a polypeptide containing the sequence of SEQ ID NO: 4 or an immunogenic fragment thereof in a test sample from the subject. Presence of the polypeptide in the test sample indicates the subject is infected with the coronavirus. One can also diagnose an infection with a coronavirus in a subject by determining presence of a specific antibody against a polypeptide having the sequence of SEQ ID NO: 4 or an immunogenic fragment thereof in the test sample. Presence of the antibody in the test sample also indicates the subject is infected with the coronavirus.
Also within the scope of this invention is a method of treating an infection with a coronavirus. The method includes administering to a subject in need thereof an effective amount of one or more of the above-described polypeptides or antibodies. The term “treating” is defined as administration of a composition to a subject with the purpose to cure, alleviate, relieve, remedy, prevent, or ameliorate a disorder, the symptom of the disorder, the disease state secondary to the disorder, or the predisposition toward the disorder. An “effective amount” is an amount of the composition that is capable of producing a medically desirable result, e.g., as described above, in a treated subject.
The details of one or more embodiments of the invention are set forth in the accompanying description below. Other advantages, features, and objects of the invention will be apparent from the detailed description and the claims.


DETAILED DESCRIPTION
This invention relates to receptor binding domains or immunogenic fragments of the S protein of a coronavirus, such as SARS. Since these domains mediate target cell binding and entry of the coronavirus or induce immune response, they can be targeted for diagnosing or treating an infection with the coronavirus.
A polypeptide of this invention contains the sequence of the S protein, such as SEQ ID NO: 4 or an immunogenic fragment thereof. It can also contain the sequence of the S protein of SARS CoV TW1, Tor-2, SIN2500, SIN2774, SIN2748, SIN2677, SIN2679, CUHK-W1, HKU39849, GZ01, BJ01, BJ02, BJ03 BJ04, and other strains. In a particular embodiment, the polypeptide contains a receptor-binding domain of the S protein or a functional equivalent. A functional equivalent of the a protein receptor binding domain refers to a polypeptide derived from the coronavirus S protein, e.g., a fusion polypeptide or a polypeptide having one or more point mutations, insertions, deletions, truncations, or a combination thereof. In particular, such functional equivalents include polypeptides, whose sequences differ from the S protein by one or more conservative amino acid substitutions or by one or more non-conservative amino acid substitutions, deletions, or insertions. Such a functional equivalent can be encoded by a nucleic acid that hybridizes under high stringency conditions to a probe the sequence of which consists of SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, or 25. The term “hybridizes under stringent conditions” refers to conditions for hybridization in 6× sodium chloride/sodium citrate (SSC) at about 45° C., followed by one or more washes in 0.2×SSC, 0.1% SDS at 50-65° C. All of the above-described functional equivalents retain substantially the receptor binding activity of coronavirus, e.g., SRAS CoV S protein, i.e., binding to target cells including VERO E6, NIH3T3. This activity can be determined by the assays described in the examples presented below.
A polypeptide of the invention can be obtained as a synthetic polypeptide or a recombinant polypeptide. To prepare a recombinant polypeptide, a nucleic acid encoding it can be linked to another nucleic acid encoding a fusion partner, e.g., Glutathione-S-Transferase (GST), 6×-His epitope tag, or M13 Gene 3 protein. The resultant fusion nucleic acid expresses in suitable host cells a fusion protein that can be isolated by methods known in the art. The isolated fusion protein can be further treated, e.g., by enzymatic digestion, to remove the fusion partner and obtain the recombinant polypeptide of this invention.
A polypeptide of the invention can be used to generate antibodies in animals (for production of antibodies) or humans (for treatment of diseases). Methods of making monoclonal and polyclonal antibodies and fragments thereof in animals are known in the art. See, for example, Harlow and Lane, (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York. The term “antibody” includes intact molecules as well as fragments thereof, such as Fab, F(ab′)2, Fv, scFv (single chain antibody), and dAb (domain antibody; Ward, et. al. (1989) Nature, 341, 544). These antibodies can be used for detecting the S polypeptide, e.g., in determining whether a test sample from a subject contains coronavirus or in identifying a compound that binds to the polypeptide. As these antibodies interfere with the cell binding and entry of the coronavirus, they are also useful for treating a coronavirus infection.
In general, to produce antibodies against a polypeptide, the polypeptide is coupled to a carrier protein, such as KLH, mixed with an adjuvant, and injected into a host animal. Antibodies produced in the animal can then be purified by peptide affinity chromatography. Commonly employed host animals include rabbits, mice, guinea pigs, and rats. Various adjuvants that can be used to increase the immunological response depend on the host species and include Freund's adjuvant (complete and incomplete), mineral gels such as aluminum hydroxide, CpG, surface-active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. Useful human adjuvants include BCG (bacille Calmette-Guerin) and Corynebacterium parvum. 
Polyclonal antibodies, heterogeneous populations of antibody molecules, are present in the sera of the immunized subjects. Monoclonal antibodies, homogeneous populations of antibodies to a polypeptide of this invention, can be prepared using standard hybridoma technology (see, for example, Kohler et al. (1975) Nature 256, 495; Kohler et al. (1976) Eur. J. Immunol. 6, 511; Kohler et al. (1976) Eur J Immunol 6, 292; and Hammerling et al. (1981) Monoclonal Antibodies and T Cell Hybridomas, Elsevier, N.Y.). In particular, monoclonal antibodies can be obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture such as described in Kohler et al. (1975) Nature 256, 495 and U.S. Pat. No. 4,376,110; the human B-cell hybridoma technique (Kosbor et al. (1983) Immunol Today 4, 72; Cole et al. (1983) Proc. Natl. Acad. Sci. USA 80, 2026, and the EBV-hybridoma technique (Cole et al. (1983) Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Such antibodies can be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD, and any subclass thereof. The hybridoma producing the monoclonal antibodies of the invention may be cultivated in vitro or in vivo. The ability to produce high titers of monoclonal antibodies in vivo makes it a particularly useful method of production.
In addition, techniques developed for the production of “chimeric antibodies” can be used. See, e.g., Morrison et al. (1984) Proc. Natl. Acad. Sci. USA 81, 6851; Neuberger et al. (1984) Nature 312, 604; and Takeda et al. (1984) Nature 314:452. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Alternatively, techniques described for the production of single chain antibodies (U.S. Pat. Nos. 4,946,778 and 4,704,692) can be adapted to produce a phage library of single chain Fv antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge. Moreover, antibody fragments can be generated by known techniques. For example, such fragments include, but are not limited to, F(ab′)2 fragments that can be produced by pepsin digestion of an antibody molecule, and Fab fragments that can be generated by reducing the disulfide bridges of F(ab′)2 fragments. Antibodies can also be humanized by methods known in the art. For example, monoclonal antibodies with a desired binding specificity can be commercially humanized (Scotgene, Scotland; and Oxford Molecular, Palo Alto, Calif.). Fully human antibodies, such as those expressed in transgenic animals are also features of the invention (see, e.g., Green et al. (1994) Nature Genetics 7, 13; and U.S. Pat. Nos. 5,545,806 and 5,569,825).
A polypeptide of the invention can also be used to prepare an immunogenic composition (e.g., a vaccine) for generating antibodies against coronavirus (e.g., SRAS CoV) in a subject susceptible to the coronavirus. Such compositions can be prepared, e.g., according to the method described in the examples below, or by any other equivalent methods known in the art. The composition contains an effective amount of a polypeptide of the invention, and a pharmaceutically acceptable carrier such as phosphate buffered saline or a bicarbonate solution. The carrier is selected on the basis of the mode and route of administration, and standard pharmaceutical practice. Suitable pharmaceutical carriers and diluents, as well as pharmaceutical necessities for their use, are described in Remington's Pharmaceutical Sciences. An adjuvant, e.g., a cholera toxin, Escherichia coli heat-labile enterotoxin (LT), liposome, immune-stimulating complex (ISCOM), or immunostimulatory sequences oligodeoxynucleotides (ISS-ODN), can also be included in a composition of the invention, if necessary. The S protein, fragments or analogs thereof or peptides may be components of a multivalent composition of vaccine against respiratory diseases. This multivalent composition contains at least one immunogenic fragment of S protein described above, along with at least one protective antigen isolated from influenza virus, para-influenza virus 3, Strentococcus pneumoniae, Branhamella (Moroxella) gatarhalis, Staphylococcus aureus, or respiratory syncytial virus, in the presence or absence of adjuvant.
Methods for preparing vaccines are generally well known in the art, as exemplified by U.S. Pat. Nos. 4,601,903; 4,599,231; 4,599,230; and 4,596,792. Vaccines may be prepared as injectables, as liquid solutions or emulsions. The S protein, fragments or analogs thereof or peptides corresponding to portions of S protein may be mixed with physiologically acceptable and excipients compatible. Excipients may include, water, saline, dextrose, glycerol, ethanol, and combinations thereof. The vaccine may further contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, or adjuvants to enhance the effectiveness of the vaccines. Methods of achieving adjuvant effect for the vaccine includes use of agents, such as aluminum hydroxide or phosphate (alum), commonly used as 0.05 to 0.1 percent solutions in phosphate buffered saline. Vaccines may be administered parenterally, by injection subcutaneously or intramuscularly. Alternatively, other modes of administration including suppositories and oral formulations may be desirable. For suppositories, binders and carriers may include, for example, polyalkalene glycols or triglycerides. Oral formulations may include normally employed incipients such as, for example, pharmaceutical grades of saccharine, cellulose, magnesium carbonate and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10-95% of the S protein, fragment analogs, or peptides.
The vaccines are administered in a manner compatible with the dosage formulation, and in an amount that is therapeutically effective, protective and immunogenic. The quantity to be administered depends on the subject to be treated, including, for example, the capacity of the individual's immune system to synthesize antibodies, and if needed, to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner. However, suitable dosage ranges are readily determinable by one skilled in the art and may be of the order of micrograms of the polypeptide of this invention. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations. The dosage of the vaccine may also depend on the route of administration and varies according to the size of the host.
Use of polypeptide in vivo may first require chemical modification of the peptides since they may not have a sufficiently long half-life. A chemically modified peptide or a peptide analog includes any functional chemical equivalent of the peptide characterized by its increased stability and/or efficacy in vivo or in vitro in respect of the practice of the invention. The term peptide analog also refers to any amino acid derivative of a peptide as described herein. A peptide analog can be produced by procedures that include, but are not limited to, modifications to side chains, incorporation of unnatural amino acids and/or their derivatives during peptide synthesis and the use of cross-linkers and other methods that impose conformational constraint on the peptides or their analogs. Examples of side chain modifications include modification of amino groups, such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH4; amidation with methylacetimidate; acetylation with acetic anhydride; carbamylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6, trinitrobenzene sulfonic acid (TNBS); alkylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxa-5′-phosphate followed by reduction with NABH4. The guanidino group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal. The carboxyl group may be modified by carbodiimide activation via o-acylisourea formation followed by subsequent derivatization, for example, to a corresponding amide. Sulfhydryl groups may be modified by methods, such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of mixed disulphides with other thiol compounds; reaction with maleimide; maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulfonic acid, phenylmercury chloride, 2-chloromercuric-4-nitrophenol and other mercurials; carbamylation with cyanate at alkaline pH. Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphonyl halides. Tryosine residues may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative. Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate. Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-isomers of amino acids.
A nucleic acid molecule of this invention may also be used directly for immunization by administration of the nucleic acid directly to a subject via a live vector, such as Salmonella, BCG, adenovirus, poxvirus or vaccinia. Immunization methods based on nucleic acids are well known in the art.
A subject susceptible to coronavirus infection can be identified and administered a polypeptide-containing composition of the invention. The dose of the composition depends, for example, on the particular polypeptide, whether an adjuvant is co-administered with the polypeptide, the type of adjuvant co-administered, the mode and frequency of administration, as can be determined by one skilled in the art. Administration is repeated as necessary, as can be determined by one skilled in the art. For example, a priming dose can be followed by three booster doses at weekly intervals. A booster shot can be given at 4 to 8 weeks after the first immunization, and a second booster can be given at 8 to 12 weeks, using the same formulation. Sera or T-cells can be taken from the subject for testing the immune response elicited by the composition against the coronavirus S protein or infection. Methods of assaying antibodies or cytotoxic T cells against a protein or infection are well known in the art. Additional boosters can be given as needed. By varying the amount of polypeptide, the dose of the composition, and frequency of administration, the immunization protocol can be optimized for eliciting a maximal immune response. Before a large scale administering, efficacy testing is desirable. In an efficacy testing, a non-human subject can be administered via an oral or parenteral route with a composition of the invention. After the initial administration or after optional booster administration, both the test subject and the control subject (receiving mock administration) are challenged with an LD95 dose of a coronavirus. End points other than lethality can also be used. Efficacy is determined if subjects receiving the composition dies at a rate lower than control subjects. The difference in death rates should be statistically significant.
The above-described S protein and its fragment can be used as a carrier and linked to other antigens of interest to generate antibodies against the antigens. The S protein or its fragment can be generally utilized to prepare chimeric molecules and conjugate compositions against pathogenic bacteria, including encapsulated bacteria. For example, the glycoconjugates of the present inventions may be applied to immunize a subject to generate antibodies against the bacteria and confer protection against infection with any bacteria having polysaccharide antigens, e.g., Haemophilus influenzae, Streptococcus pneumoniae, Escherichia coli, Neisseria meningitidis, Salmonella typhi, Streptococcus mutans, Cryptococcus neoformans, Klebsiella, Staphylococcus aureus, and Pseudomonas aeruginosa. In addition, as a carrier, the S protein or fragment may be used to induce immunity toward abnormal polysaccharides of tumor cells, thereby to produce anti-tumor antibodies for chemotherapy or diagnosis.
Also within the scope of this invention is a diagnosing method using the above-described polypeptides or antibodies. Presence of the polypeptides or antibodies in a subject indicates that the subject is infected with a coronavirus. To detect the antibodies or polypeptides, one can obtain a test sample from a subject and detect the presence or absence of the antibodies or polypeptides using standard techniques, including ELISAs, immunoprecipitations, immunofluorescence, EIA, RIA, and Western blotting analysis.
The nucleic acid of this invention is useful as a hybridization probe for identifying coronavirus, e.g., SARS CoV, in a sample. The sample can be a clinical sample, including exudates, body fluids (e.g., serum, amniotic fluid, middle ear effusion, sputum, bronchoalveolar lavage fluid) and tissues. A variety of hybridization conditions may be employed to achieve varying degrees of selectivity of the probe toward the target sequences. A high degree of selectivity requires stringent conditions, such as that described in the Summary section
A hybridization reaction can be performed both in a solution or on a solid phrase. In a solid phase, a test sequence from a sample is affixed to a selected matrix or surface. The fixed nucleic acid is then subjected to specific hybridization with selected probes comprising the nucleic acid of the present invention under desired conditions. The selected conditions will depend on the particular circumstances based on the particular criteria required depending on, for example, on the G+C contents, type of target nucleic acid, source of nucleic acid, size of hybridization probe etc. Following washing of the hybridization surface to remove non-specifically bound probe molecules, specific hybridization is detected or quantified, by means of the label. The selected probe should be at least 18 bp and may be in the range of 30 bp to 90 bp long.
In addition, A small interference RNA (SiRNA) corresponding to the nucleotide sequences of the present invention comprising the sequence of the S protein receptor binding domains such as RBD1 and RBD2, can be useful to block SARS CoV replication in vivo.
A polypeptide of this invention can also be used in a screening method of identifying a compound for treating an infection with a coronavirus, e.g., SARS CoV. The method includes (1) contacting a polypeptide of this invention with a suitable cell, to which the coronavirus binds to; and (2) determining a binding level between the polypeptide and the cell the presence or absence of a test compound. The binding level in the presence of the test compound, if lower than that in the absence of the test compound, indicates that the test compound can be used to treat an infection with the coronavirus. Examples of the cell include VERO E6 cells, NIH3T3 cells, HeLa cells, BHK-21 cells, and COS-7 cells. One can also use other cells that are capable of binding to a coronavirus.
The above-described polypeptides and antibodies can be used for treating an infection with a coronavirus, e.g., SARS. The invention therefore features a method of treating SARS, e.g., by administering to a subject in need thereof an effective amount of a polypeptide, an antibody, or a compound of the invention. Subjects to be treated can be identified as having, or being at risk for acquiring, a condition characterized by SARS. This method can be performed alone or in conjunction with other drugs or therapy.
Thus, also within the scope of this invention is a pharmaceutical composition that contains a pharmaceutically acceptable carrier and an effective amount of a polypeptide, an antibody, or a compound of the invention. The pharmaceutical composition can be used to treat coronavirus infection, such as SARS. The pharmaceutically acceptable carrier includes a solvent, a dispersion medium, a coating, an antibacterial and antifungal agent, and an isotonic and absorption delaying agent.
In one in vivo approach, a composition of this invention (e.g., a composition containing a polypeptide, an antibody, or a compound of the invention) is administered to a subject. Generally, the antibody or the compound is suspended in a pharmaceutically-acceptable carrier (e.g., physiological saline) and administered orally or by intravenous infusion, or injected or implanted subcutaneously, intramuscularly, intrathecally, intraperitoneally, intrarectally, intravaginally, intranasally, intragastrically, intratracheally, or intrapulmonarily.
The dosage required depends on the choice of the route of administration; the nature of the formulation; the nature of the subject's illness; the subject's size, weight, surface area, age, and sex; other drugs being administered; and the judgment of the attending physician. Suitable dosages are in the range of 0.01-100.0 mg/kg. Wide variations in the needed dosage are to be expected in view of the variety of compositions available and the different efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization as is well understood in the art. Encapsulation of the composition in a suitable delivery vehicle (e.g., polymeric microparticles or implantable devices) may increase the efficiency of delivery, particularly for oral delivery.
A pharmaceutical composition of the invention can be formulated into dosage forms for different administration routes utilizing conventional methods. For example, it can be formulated in a capsule, a gel seal, or a tablet for oral administration. Capsules can contain any standard pharmaceutically acceptable materials such as gelatin or cellulose. Tablets can be formulated in accordance with conventional procedures by compressing mixtures of the composition with a solid carrier and a lubricant. Examples of solid carriers include starch and sugar bentonite. The composition can also be administered in a form of a hard shell tablet or a capsule containing a binder, e.g., lactose or mannitol, conventional filler, and a tableting agent. The pharmaceutical composition can be administered via the parenteral route. Examples of parenteral dosage forms include aqueous solutions, isotonic saline or 5% glucose of the active agent, or other well-known pharmaceutically acceptable excipient. Cyclodextrins, or other solubilizing agents well known to those familiar with the art, can be utilized as pharmaceutical excipients for delivery of the therapeutic agent.
The efficacy of a composition of this invention can be evaluated both in vitro and in vivo. Briefly, the composition can be tested for its ability to inhibit the binding between a coronavirus and its target cell in vitro. For in vivo studies, the composition can be injected into an animal (e.g., a mouse model) and its therapeutic effects are then accessed. Based on the results, an appropriate dosage range and administration route can be determined.
The specific examples below are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. Without further elaboration, it is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. All publications cited herein are hereby incorporated by reference in their entirety.
EXAMPLE 1
In this example, the gene encoding S protein of SARS CoV was cloned. A SARS CoV, designated as “SARS-CoV TW1,” was isolated from a SARS patient in Taiwan. Seven pairs of PCR primers were designed based on the sequence of the Urbani strain (SEQ ID NO: 1) or the SARS CoV TOR2 strain. The positions of the primers' 5′ ends within the Urbani genome were summarized below:
















5′ primer
3′ primer









Pair 1
21,492
22,000



Pair 2
22,000
22,600



Pair 3
22,600
23,100



Pair 4
23,075
23,780



Pair 5
23,765
24,320



Pair 6
24,300
24,875



Pair 7
24,850
25,244










Seven products were generated by PCR reactions respectively and ligated together to form a sequence that encoded the S protein. The sequence was then subcloned into pUC19 to produce pUC19/S and used to transform E. coli HB101. Plasmid DNA was prepared from two E. coli HB101 colonies and sequenced on an ABI 370A DNA sequencer. Subsequent sequence analysis revealed that the sequence differed from that of the TOR2 strain by 3 base pairs and that it is about 30.1% identical to that of human coronavirus 229E.
SARS CoV M and E proteins (GenBank Accession Nos. AAP 13443 and 13444) were also cloned and expressed. The E-M fusion protein corresponds to residues 8751 to 9057 of the first open reading frame of SEQ ID NO: 1. Construction of DNA plasmids containing genes for E and M proteins was performed by standard molecular biology methods (Sambrook et al (1989) Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor Laboratory. Cold Spring Harbor, N.Y.). The constructs utilized a pUC-based expression vector, which was shown to result in optimal expression of reporter genes. Each vector employed the human cytomegalovirus promoter, enhancer, intron A, and the bovine growth hormone termination and polyasenylation sequences. The tissue plasminogen activator signal sequence was use to enhance the level of expression. The M and E proteins were further expressed in host cells to generated virus like particles.
EXAMPLE 2
It is known that, in SARS CoV, the S native protein is expressed in small quantities. To obtain a large amount of the S protein, there is a need to either express it in a heterologous system, such as E. coli, or to modify SARS CoV to increase the native S protein expression.
The above-described PUC19/S was transformed into E. coli. to express the S protein. It was found that the full-length recombinant S (rS) protein was not expressed in E. coli. Vectors encoding different S protein fragments fused to Myc-His tag were then constructed and transformed in E. coli. The fragments include the N-terminal amino acids 80-228 of the S protein (receptor binding domain 1; RBD1); the middle region encompassing amino acids 284-735 of the S protein (receptor binding domain 2; RBD2), the transmembrane domain (TM), and fusions of them.
To examine the expressed protein, antisera against various SARS CoV proteins were generated The following SARS CoV polypeptides were synthesized by standard techniques:








RBD1-specific
KSGNFKHLREFVFKNKDGFLYVYKGQPIDV


peptide
(SEQ ID NO:29)


 


RBD2-specific
GNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPC


peptide
(SEQ ID NO:24)


 


TM-specific
DSFKEELDRY FKNHTSPDVD LGDISGINAS VV


peptide
(SEQ ID NO:30)


 


E-specific
ALRLCAYCCN IVNVSLVKPT VYVYSRVKNL


peptide
NSSEG (SEQ ID NO:31)


 


M-specific
MADNGTITVE ELKQLLEQWN LVICFLFLWA IML


peptide
(SEQ ID NO:32)






More specifically, 200 μg of each peptide was mixed with the completed Fruend's adjuvant and injected at day 0 and injected into rabbits by standard techniques At day 14 and 56, the rabbits were boosted with half of the amount of the peptide in the incomplete Fruend's adjuvant At day 78, the rabbits were bleed, and the blood were tested for antiserum titer by ELISA The results are shown in Table 1








TABLE 1







Rabbit immunogenicity of SARS CoV peptides


Reactivity of Anti-peptide sera to target peptide












Peptides
Pre-Immune
Post-booster
Final Bleed







RBD1-specific
0
5120
10240



RBD2-specific
0
10240 
41440



TM-specific
0
5120
10240



E-specific
0
1280
 5120



M-specific
0
5120
10240










To generate a vector encoding RBD1, the following two primers were used for PCR: 5′ primer: GGATCCGCCACC ATG catacgtttg g (SEQ ID NO:33); and 3′ primer: aa ttttagagcc GAATTC (SEQ ID NO:34) The two primers contained EcoRI and BamHI sites to facilitate subsequent cloning of PCR products A  ̃500 base pair (bp) fragment was obtained and subcloned into pcDNA-A4 to generate pcDNA-A4-D1 plasmid, which encoded a fusion protein of Myc-His-RBD This plasmid was transformed into E coli HB101 to express recombinant RBD1 (rRBD1) It was found that, upon induction, the transformed clones expressed a 20 kDa protein This protein was expressed at high levels in inclusion bodies and was recognized by anti-RBD-1 antisera and anti-His tag antibody on Western blot analysis It was also found that protein was highly immunogenic, but not able to elicit protective antibodies against live virus challenge
A vector encoding RBD2 was also generated More specifically, PCR was conducted using the following two primers 5′ primer: GGATCCGCCACCATG gagattgaca (SEQ ID NO:35) and 3′ primer: aatatgg GCGGCCGC (SEQ ID NO:36) to generate a 14 kb fragment After being digested by BamH1-Not1, the resulting fragment was also subcloned into pcDNA-A4 The resultant vector was used to express RBD2 in the same manner described above It was found that a 50-kDa protein was expressed at high levels in both soluble form and in inclusion bodies Western blot analysis revealed that this protein was recognized by the S-specific antisera This rRBD2 fragment was highly immunogenic too and elicited even stronger neutralizing antibodies that could block SARS CoV binding to Vero cell (see Example 9 below)
The above-described recombinant proteins were isolated from E. coli. More specifically, E. coli pellet from a 250 mL culture was resuspended in 40 mL of 50 mM Tris, pH 8.0, and disrupted by sonication (3×10 minutes, 70% duty circle). The resultant mixture was centrifuged at 20,000×g. The pellet was re-extracted with 40 mL of 50 mM Tris, 0.5% Triton X-100, 10 mM EDTA, pH 8.0. The suspension was then sonicated for 10 minutes at 70% duty circle and centrifuged at 300×g for 5 minutes. The resulting supernatant was centrifuged again at 20,000×g for 30 minutes. The pellet was resuspended in 50 mM Tris, 0.5% Triton X-100, 10 mM EDTA, pH 8.0 and mixed with PBS/8 M urea to a final urea concentration of 6 M urea. The mixture was then dialyzed against PBS to remove urea and centrifuged at 300×g for 10 minutes. The supernatant was saved and stored at 4° C.
Ni-affinity chromatography was used to isolate rRBD1 and rRBD2 fusion proteins from inclusion body. The just described supernatant was loaded onto a Ni affinity column (2 mL) equilibrated with PBS containing 1% Triton X-100. The run-through of the column was discarded. After washing the column with 20 mL of PBS, the affinity column was eluted with 50 mM Tris-HCl buffer, pH 8.0, containing 5 mM EDTA. The protein-containing factions were collected and the purity was analyzed by SDS-PAGE.
It was estimated that about 10 mg of rRBD2 was recovered from 1 L of E. coli bacterial culture. The identity of rRBD2 was confirmed by both immunoblotting and protein sequencing. The N-terminal sequence of this polypeptide was found to be Met-Ala-Glu-Leu-Lys-Cys, which corresponds to residues 284 to 288 of the sequence of S protein.
EXAMPLE 3
In this example, additional fragments of the SARS coronavirus S protein were expressed in baculovirus and SF21 insect cell.
Nucleic acids encoding 1-333, 334-666, and 667-999 amino acid of the S protein (spike1, spike2, and spike3; S1, S2, and S3, respectively) were obtained by PCR with primer sets listed below, respectively, in the manner similar to that described in Example 1













Amplified
Primer




fragment
name
Sequence (5′ to 3′)
Sense







Spike1
S1F
AGGGATCCATGTTTATTTTCTTATTATTTCTTACTC
S


(1-333 aa)
S1R
CCTGGATCCTTTAGTAGCATTAAAAACCTCTCCA
AS


 


Spike2
S2F
AGGGGATCCTTCCCTTCTGTCTATGCATGGGAGA
S


(334-666 aa)
S2R
CCTGGATCCTAATAAAGAAACTGTATGGTAACTA
AS


 


Spike3
S3F
AGGGGATCCCGTAGTACTAGCCAAAAATCTATTG
S


(667-999 aa)
S3R
CCTGGATCCTTCAGCAGCCCTGATTAGTTGTTGT
AS


 


RBD1
RBD1F
CATACGTTTGGCAACCCTGTC
S


(74-253 aa)
RBD1R
AACATTACAAATTTTAGAGCC
AS


 


RBD2
RBD2F
GAGATTGACAAAGGAATTTAC
S


(294-73 9 aa)
RBD2R
CTAATTTGCTTCTCCAATATGG
AS


 


RBD3
RBD3F
ATGGCTAAAACCTCCGTAGAT
S


(713-1113 aa)
RBD3R
AATTGTGATGTCGTTATTGGC
AS


 


TM
TM1F
ACTTCAAAAATCATACATCA
S


(1130-1255 aa)
TM1R
GGTGTCAAATTACATTACACATAA
AS





SEQ ID NOs 37-50, respectively






The PCR products were inserted into the pCR2.1 vector by TA cloning. The coding sequences were than released by BamHI digestions and ligated to BamHI-cutted pSecTagb/hIgG1.Fc vector, thereby in-frame fusing the S protein-encoding sequence to that encoding the human IgG1 Fc, The resultant vectors encodes fusion proteins spike 1-Fc, spike2-Fc, and spike3-Fc. To generate corresponding baculovirus transfer vectors, the three fusion genes were released by NheI/XhoI digestion and ligated to XbaI/XhoI-cutted pBacPAK9 vectors.
The just-described pBacPAK9 vectors were co-transfected into Sf21 cells with Bsu36 I-digested BacPAK6 viral DNA by Bacfectin (Clontech 6144-1). Each resulting viral plaque was picked by performing plaque assays on the co-transfection supernatant. The recombinant viruses were confirmed by PCR. Sf21 cells were then infected with virus at a small scale to characterize gene expression and to determine the optimum harvest time and infection ratio by standard methods. Recombinant viruses were amplified to high virus titer to obtain working stocks for large-scale infection.
To purify recombinant proteins, Sf21 cells were cultured in spinner flask at a starting concentration of 2×105/ml in the first 3-5 days. After reaching 1-2×106 cells/ml, the cells were infected with the above-described recombinant baculoviruses at M.O.I. of 5-10 and cultured for 4-5 days. The supernatants were then collected and cell debris was removed by centrifugation. The supernatant was loaded onto protein A Sepharose® 4 Fast Flow beads (Amersham Biosciences 17-0974). Finally, the bound Fc-fusion protein was eluted with a 0.1 M glycine buffer (pH 3.0), followed by dialysis against PBS. The purity and the concentration of purified proteins were assessed by a standard silver staining method.
Five milligrams of S1-Fc fusion protein crude extract prepared in the manner described above were dissolved in 5 mL of phosphate buffer saline (PBS) containing 1% Triton X-100. The solution was then loaded onto a Protein A-Sepharose 4B column (2 mL) equilibrated with PBS containing 1% Triton X-100. The run-through of the column was discarded. The column was washed with 20 mL of PBS and the S1-Fc fusion protein was eluted with 50 mM Gly-HCl buffer, pH 3.0. Elution was monitored by absorbance at 280 nm. Protein-containing fractions (2 mL/fraction) were collected and pooled. The purity of the protein was assessed by SDS-PAGE.
Certain plasmids described above was deposited with the American Type Culture Collection (ATCC) located at 10801 University Boulevard, Manassas, Va. 20110-2209 U.S.A. pursuant to the Budapest Treaty and prior to the filing of this application. Samples of the deposited plasmids will become available to the public upon grant of a patent based upon this United States patent application.
EXAMPLE 4
The above-described recombinant RBD1, RBD2, S1-FC, and S2-Fc were used to produce of S-specific antisera. The purified recombinant proteins were emulsified in the Freund's complete adjuvant (Difco) and injected intramuscularly (IM) into New Zealand White rabbits (Maple Lane) or guinea pigs (Charles River) at a dose of 10 to 100 μg/injection. The animals were boosted on day 28 with another half of dose of the corresponding S fragment emulsified in Freund's incomplete adjuvant. On day 42, a blood sample was taken from each animal via the marginal ear vein for titer determination by standard methods. Animals that generated specific antibodies were bled to obtain more antisera.
To examine the immunogenicity of the RBD1 or 2 fusion protein, guinea pigs or mice were immunized with RBD1 or 2 of various amounts. The doses between 10 to 100 μg/injection RBD1 induced high IgG titers in guinea pigs when administered in the presence of either Freund's adjuvant or AlPO4. In the mice, RBD1 or 2 appeared to be immunogenic at a dose as low as 5 μg/injection in either Freund's adjuvant.
A ferret model was used to examine the protective ability of anti-RBD1 or 2 sera against a SARS CoV infection. It was found that ferrate passively immunized with guinea pig anti-RBD2 antisera, but not anti-RBD1 sera, were significantly protected than controls injected with pre-immune sera.
The above-described S1-Fc or S2-Fc fusion protein was used to purify S protein-specific polyclonal antibodies by affinity chromatography. The recombinant S1-Fc or S2-Fc fusion protein was conjugated to cyanogen bromide-activated Sepharose to form an affinity column. The affinity column was then used to purify antibodies from a rabbit hyperimmune anti-inactivated SARS CoV antiserum. The affinity purified-antibodies were shown by immunoblotting to react with a 200-kDa component present in the lysates of SARS Cov isolates. Similarly, antisera raised against the recombinant fusion protein or the purified RBD1, RBD2, S1 and S2 can also be purified in the same manner.
EXAMPLE 5
Purified recombinant RBD2 were conjugated with S. pneumococcal oligosaccharides 14 (14F) by periodate oxidation in the manner described in U.S. Pat. No. 4,356,170. S. pneumococcal oligosaccharides 14 was prepared by controlled acid hydrolysis. The mean molecular size of the 14F molecules used for conjugation was determined as approximately 20,000 Daltons. The conjugation was carried out with or without a linker molecule. A 14/RBD2 molar ratio of approximately 7 was used to provide an excess of 14F hapten.
To prepare 14-BSA conjugates, 0.5 mL of periodate-oxidized 14 (25 mg in 1 mL of 0.1 M sodium phosphate buffer, pH 6.0), prepared from native 14F treated with aqueous periodic acid (Carlone et al, 1986 J. Clin. Microbiol. 24:330-331.), was added to bovine serum albumin (BSA) (1.32 mg; 0.02 μmol) in 0.5 mL of 0.2 M sodium phosphate buffer, pH 8.0, followed by the addition of sodium cyanoborohydride (14 μg; 0.22 μmol; 10 eqv. to BSA). After incubation at 37° C. for 5 days, the reaction mixture was dialyzed against 4 L of 0.1 M phosphate buffer, pH 7.5. The resulting solution was applied onto an analytical Superose 12 column (15×0.300 mm, Pharmacia) equilibrated with 0.2 M sodium phosphate buffer, pH 7.2, and eluted with the same buffer. Fractions were monitored for absorbance at 230 nm. The first major protein peak was pooled and concentrated in a Centriprep 30 to 2.2 mL. The amount of protein was found, by the Bio Rad protein assay, to be 300 ug/mL. The presence of 14 oligosaccharides in the protein conjugate fraction was confirmed by the Orcinol test.
The above-described RBD2-14 S. pneumococcal polysaccharide conjugate was then used to produce anti-14 S. pneumococcal polysaccharide antisera in animals. Rabbits were immunized intramuscularly with 14-RBD2 conjugates (5 to 50 μg 14 equivalent) mixed with 3 mg AlPO4 per mL, followed by two booster doses (half amount of the same immunogen) at 2-week intervals. Antisera were collected every 2 weeks after the first injection, heat-inactivated at 56° C. for 30 minutes and stored at −20° C. It was found that the immunization elicited both primary and secondary immune responses against PRP-IgG and S protein. Rabbit anti-RBD2-14F antisera also strongly reacted with both native S and rS as determined by immunoblot analysis. These results indicate that RBD2 can be used as a carrier protein in a conjugate vaccine. Since RBD2-14 S. pneumococcal polysaccharide conjugate elicited antibodies against both 14F and S, it can be used to d thus should enhance the level of protection against S. pneumococcal-related diseases, especially in infants.
EXAMPLE 6
To map the linear B-cell epitopes of the SARS S protein, overlapping synthetic peptides covering the entire S protein were synthesized. These peptides were listed in Table 2 below.







TABLE 2







Synthetic SARS CoV S peptides










Peptide ID





No
MW
Sequence
SEQ ID NO:










RED1-related fragments










  1
1,6812
VIPFKDGIYFAATEK
51


 


  2
1,6520
DGIYFAATEKSNVVR
52


 


  3
1,6029
AATEKSNVVRGWVFG
53


 


  4
1,6499
SNVVRGWVFGSTMNN
54


 


  5
1,6238
GWVFGSTMNNKSQSV
55


 


  6
1,6449
STMNNKSQSVIIINN
56


 


  7
1,5978
KSQSVIIINNSTNVV
57


 


  8
1,6261
IIINNSTNVVIRACN
58


 


  9
1,6661
STNVVIRACNFELCD
59


 


 10
1,7423
IRACNFELCDNPFFA
60


 


 11
1,7272
FELCDNPFFAVSKPM
61


 


 12
1,6439
NPFFAVSKPMGTQTH
62


 


 13
1,6750
VSKPMGTQTHTMIFD
63


 


 14
1,6820
GTQTHTMIFDNAFNC
64


 


 15
1,8113
TMIFDNAFNCTFEYI
65


 


 16
1,7111
NAFNCTFEYISDAFS
66


 


 17
1,7050
TFEYISDAFSLDVSE
67


 


 18
1,5849
SDAFSLDVSEKSGNF
68


 


 19
1,7412
LDVSEKSGNFKHLRE
69


 


 20
1,8334
KSGNFKHLREFVFKN
70


 


 21
1,8605
KHLREFVFKNKDGFL
71


 


 22
1,8074
FVFKNKDGFLYVYKG
72


 


 23
1,7882
KDGFLYVYKGYQPID
73


 


 24
1,8101
YVYKGYQPIDVVRDL
74


 


 25
1,7019
YQPIDVVRDLPSGFN
75


 


 26
1,6381
VVRDLPSGFNTLKPI
76


 


 27
1,6543
PSGFNTLKPIFKLPL
77


 







RBD2-related fragments










 28
1,6362
AELKCSVKSFEIDKG
78


 


 29
1,6840
SVKSFEIDKGIYQTS
79


 


 30
1,7510
EIDKGIYQTSNFRVV
80


 


 31
1,6638
IYQTSNFRVVPSGDV
81


 


 32
1,6849
NFRVVPSGDVVRFPN
82


 


 33
1,6140
PSGDVVRFPNITNLC
83


 


 34
1,6881
VRFPNITNLCPFGEV
84


 


 35
1,6361
ITNLCPFGEVFNATK
85


 


 36
1,6850
PFGEVFNATKFPSVY
86


 


 37
1,8262
FNATKFPSVYAWERK
87


 


 38
1,8103
FPSVYAWERKKISNC
88


 


 39
1,7522
AWERKKISNCVADYS
89


 


 40
1,6581
KISNCVADYSVLYNS
90


 


 41
1,6960
VADYSVLYNSTFFST
91


 


 42
1,7593
VLYNSTFFSTFKCYG
92


 


 43
1,6692
TFFSTFKCYGVSATK
93


 


 44
1,6443
FKCYGVSATKLNDLC
94


 


 45
1,6561
VSATKLNDLCFSNVY
95


 


 46
1,6891
LNDLCFSNVYADSFV
96


 


 47
1,6449
FSNVYADSFVVKGDD
97


 


 48
1,6018
ADSFVVKGDDVRQIA
98


 


 49
1,5226
VKGDDVRQIAPGQTG
99


 


 50
1,5697
VRQIAPGQTGVIADY
100


 


 51
1,6179
PGQTGVIADYNYKLP
101


 


 52
1,7432
VIADYNYKLPDDFMG
102


 


 53
1,7543
NYKLPDDFMGCVLAW
103


 


 54
1,7372
DDFMGCVLAWNTRNI
104


 


 55
1,6470
CVLAWNTRNIDATST
105


 


 56
1,6859
NTRNIDATSTGNYNY
106


 


 57
1,8112
DATSTGNYNYKYRYL
107


 


 58
1,9276
GNYNYKYRYLRHGKL
108


 


 59
2,0017
KYRYLRHGKLRPFER
109


 


 60
1,8063
RHGKLRPFERDISNV
110


 


 61
1,7580
RPFERDISNVPFSPD
111


 


 62
1,5589
DISNVPFSPDGKPCT
112


 


 63
1,5229
PFSPDGKPCTPPALN
113


 


 64
1,6422
GKPCTPPALNCYWPL
114


 


 65
1,7522
PPALNCYWPLNDYGF
115


 


 66
1,7832
CYWPLNDYGFYTTTG
116


 


 67
1,6789
NDYGFYTTTGIGYQP
117


 


 68
1,6989
YTTTGIGYQPYRVVV
118


 


 69
1,7651
IGYQPYRVVVLSFEL
119


 


 70
1,6731
YRVVVLSFELLNAPA
120


 


 71
1,5140
LSFELLNAPATVCGP
121


 


 72
1,4689
LNAPATVCGPKLSTD
122


 


 73
1,5990
TVCGPKLSTDLIKNQ
123


 


 74
1,7191
KLSTDLIKNQCVNFN
124


 


 75
1,7071
LIKNQCVNFNFNGLT
125


 


 76
1,5380
CVNFNFNGLTGTGVL
126


 


 77
1,4609
FNGLTGTGVLTPSSK
127


 


 78
1,6039
GTGVLTPSSKRFQPF
128


 


 79
1,7928
TPSSKRFQPFQQFGR
129


 


 80
1,8558
RFQPFQQFGRDVSDF
130


 


 81
1,7387
QQFGRDVSDFTDSVR
131


 


 82
1,6508
DVSDFTDSVRDPKTS
132


 


 83
1,6710
TDSVRDPKTSEILDI
133


 


 84
1,6181
DPKTSEILDISPCAF
134


 


 85
1,4890
EILDISPCAFGGVSV
135


 


 86
1,3748
SPCAFGGVSVITPGT
136


 


 87
1,3576
GGVSVITPGTNASSE
137


 


 88
1,5038
ITPGTNASSEVAVLY
138


 


 89
1,5937
NASSEVAVLYQDVNC
139


 


 90
1,6087
VAVLYQDVNCTDVST
140


 


 91
1,5707
QDVNCTDVSTAIHAD
141


 


 92
1,5217
TDVSTAIHADQLTPA
142


 


 93
1,7241
AIHADQLTPAWRIYS
143


 


 94
1,7019
QLTPAWRIYSTGNNV
144


 


 95
1,7668
WRIYSTGNNVFQTQA
145


 


 96
1,5047
TGNNVFQTQAGCLIG
146


 


 97
1,5708
FQTQAGCLIGAEHVD
147


 


 98
1,5791
GCLIGAEHVDTSYEC
148


 


 99
1,6310
AEHVDTSYECDIPIG
149


 


100
1,4951
TSYECDIPIGAGICA
150


 


101
1,4991
DIPIGAGICASYHTV
151


 


102
1,5602
AGICASYHTVSLLRS
152


 


103
1,6760
SYHTVSLLRSTSQKS
153


 


104
1,6360
SLLRSTSQKSIVAYT
154


 


105
1,5389
TSQKSIVAYTMSLGA
155


 


106
1,4810
IVAYTMSLGADSSIA
156


 


107
1,5129
MSLGADSSIAYSNNT
157


 


108
1,5489
DSSIAYSNNTIAIPT
158


 


109
1,6240
YSNNTIAIPTNFSIS
159


 


110
1,5880
IAIPTNFSISTTTEV
160


 


111
1,6380
NFSISITTEVMPVSM
161


 


112
1,5759
ITTEVMPVSMAKTSV
162


 


113
1,6591
MPVSMAKTSVDCNMY
163


 


114
1,5891
AKTSVDCNMYICGDS
164


 


115
1,6211
DCNMYICGDSTECAN
165


 







TM-related Fragments










116
1,8833
DSFKEELDKYFKNHT
166


 


117
1,7901
ELDKYFKNHTSPDVD
167


 


118
1,6270
FKNHTSPDVDLGDIS
168


 


119
1,4418
SPDVDLGDISGINAS
169


 


120
1,4818
LGDISGINASVVNIQ
170


 


121
1,6379
GINASVVNIQKEIDR
171


 


122
1,7219
VVNIQKEIDRLNEVA
172


 


123
1,7671
KEIDRLNEVAKNLNE
173


 


124
1,6671
LNEVAKNLNESLIDL
174


 


125
1,6961
KNLNESLIDLQELGK
175


 


126
1,7941
SLIDLQELGKYEQYI
176


 


127
2,0132
QELGKYEQYIKWPWY
177


 


128
2,0604
YEQYIKWPWYVWLGF
178


 


129
1,8315
KWPWYVWLGFIAGLI
179


 


130
1,5843
VWLGFIAGLIAIVMV
180


 


131
1,5254
IAGLIAIVMVTILLC
181


 


132
1,5834
AIVMVTILLCCMTSC
182


 


133
1,6046
TILLCCMTSCCSCLK
183


 


134
1,4824
CMTSCCSCLKGACSC
184


 


135
1,4354
CSCLKGACSCGSCCK
185


 


136
1,5221
GACSCGSCCKFDEDD
186


 


137
1,6260
GSCCKFDEDDSEPVL
187


 


138
1,6730
FDEDDSEPVLKGVKL
188


 







S3 Fragments










S3-1

GDSTECANLLLQYGS
189


 


S3-2

LQYGSFCTQLNRALS
190


 


S3-3

NRALSGIAAEQDRNT
191


 


S3-4

QDRNTREVFAQVKQM
192


 


S3-5

QVKQMYKTPTLKYFG
193


 


S3-6

LKYFGGFNFSQILPD
194


 


S3-7

QILPDPLKPTKRSFI
195


 


S3-8

KRSFIEDLLFNKVTL
196


 


S3-9

KVTLLADAGFMKQYG
197


 


S3-10

MKQYGECLGDINARD
198


 


S3-11

INARDLICAQKFNGL
199


 


S3-12

KFNGLTVLPPLLTDD
200


 


S3-13

LLTDDMIAAYTAALV
201


 


S3-14

TAALVSGTATAGWTF
202


 


S3-15

AGWTFGAGAALQIPF
203


 


S3-16

LQIPFAMQMAYRFNG
204


 


S3-17

YRFNGIGVTQNVLYE
205


 


S3-18

NVLYENQKQIANQFN
206


 


S3-19

ANQFNKAISQIQESL
207


 


S3-20

IQESLTTTSTALGKL
208


 


S3-21

ALGKLQDVVNQNAQA
209


 


S3-22

QNAQALNTLVKQLSS
210


 


S3-23

KQLSSNFGAISSVLN
211


 


S3-24

SSVLNDILSRLDKVEA
212


 


S3-25

LDKVEAEVQIDRLITG
213


 


S3-26

RLITGRLQSLQTYVTQQLIRA
214


 








RBD2
GNYNYKYRYLRHGKLRPFERDISNVPF



SPDGKPC (SEQ ID NO:24)


 


RBD55
DPKTSEILDISPCAFGGVSVITPGTNA



SSEVAVLYQDVNCTDVSTAIHAD



(SEQ ID NO:26)





Note: RBD-55 includes the amino acids covering S84 to S91






The peptides were synthesized by an ABI 433A peptide synthesizer and optimized F-Moc chemistry according to the manufacturer's manual. The synthesized peptides were cleaved from the resin by Trifluoroacetic acid (TFA). They were then purified by reversed-phase high performance liquid chromatography (RP-HPLC) on a Vydac C4 semi-preparative column (1×30 cm) using a 15 to 55% acetonitrile gradient in 0.1% trifluoryl acetic acid (TFA) developed over 40 minutes at a flow rate of 2 mL/min. All synthetic peptides used in subsequent biochemical and immunological studies were >95% pure as determined by analytical HPLC. Amino acid compositions of these peptides were determined on a Waters Pico-Tag system. The results indicated a good agreement with their expected compositions.
ELISA was used to map B-cell epitopes. Microtiter wells (Nunc-Immunoplate, Nunc, Denmark) were coated with 50 μL of a coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) containing 200 ng of purified recombinant S fragments or 500 ng of individual peptides (listed in Table 3 below) for 16 hours at room temperature. The plates were then blocked in 0.1% (w/v) BSA in phosphate buffer saline (PBS) for 30 minutes at room temperature. Serially diluted antisera were added to the wells and incubated for 1 hour at room temperature. After removal of the antisera, the plates were washed five times with PBS containing 0.1% (w/v) Tween-20 and 0.1% (w/v) BSA. Fab′2 fragments from goat anti-rabbit, -guinea pig, -mouse, or -human IgG antibodies conjugated to horseradish peroxidase (Jackson ImmunoResearch Labs Inc., PA) were diluted (1/8,000) with a washing buffer, and added to the microtiter wells. After incubating for 1 hour at room temperature, the wells were washed five times with the washing buffer and then developed using the substrates tetramethylbenzidine (TMB) and H2O2 (ADI, Toronto). The reaction was stopped by adding 1N H2 SO4 and the optical density was measured at 450 nm by a Titretek Multiskan II (Flow Labs., Virginia). Two irrelevant peptides were used as negative controls. All assays were performed in triplicate, and the reactive titer of each antiserum was defined as the dilution consistently showing 2-fold increase absorbance value over those obtained from the negative controls. Immunodomiant B-cell epitopes were identified to residues 125-146, 334-348, 409-423, 449-468, 589-603, and 1232-1246. These results indicate that these regions contain the linear B-cell epitope sequences and that they can be used as target antigens in, e.g., diagnostic kits to detect the presence of anti-S and anti-SARS CoV antibodies in samples.
EXAMPLE 7
It is known that SRAS CoV binds to VERO E6 cells. The above-described S protein fragments were tests for their ability to bind to VERO E6 cells. Vero E6 cells (1×104 cells per mL) were incubated with S1-Fc, S2-Fc, S3-Fc, or human IgG1 at various concentrations in a volume of 1 mL for 2 hours at room temperature. The cells were then washed in PBS containing 0.5% BSA and 0.1% NaN3, incubated with FITC-labeled goat anti-human IgG Fc (Sigma), and analyzed by flow cytometry. It was found that S1-Fc and S2-Fc bound to VERO E6 cells at 1 μg/ml and 0.1 g/ml, respectively. In contrast, S3-fc and human IgG1 did not bind to VERO E6 cell even at 10 μg/ml.
The just-described VERO E6 cell model was used to examine the ability of anti-S1-Fc or anti-S2-Fc serum to inhibit the binding of SARS CoV to VERO E6 cells. VERO E6 cells were cultured on a 24-well plate until they reached approximately 50% confluent. The cells were then incubated with SARS-CoV Tw1 strain (MOI 1:10) and human sera that had a 1/128 virus neutralization titer in the presence or absence of 0.1 to 10 μg/mL corresponding S fusion proteins. After 24-48 hours, the cells were examined under a microscope. The presence of multinucleated giant cells indicated infected cells. The results indicated that human sera blocked the viral infection, and that this blocking activity was repressed by the recombinant S fusion proteins.
EXAMPLE 8
Since S2-Fc fusion protein strongly bound to VERO E6 cell and inhibited human neutralizing antibody activity against SARS CoV, it was of interest to identify the protective epitope(s) of this S2 fragment. Eighty-eight peptides from S2 (shown in Table 2 above) were synthesized based upon the sequence of the SARS CoV TW1 S protein.
Five convalescent sera were obtained from patients infected with SARS CoV and three sera were obtained from guinea pigs immunized with RBD2 in the manner described in Examples 5 and 6 above. These antisera were mixed with the peptides shown in Table 3. These peptides covered residues 522 to 600 of the S protein. The reactive titer of each antiserum was determined. The results are summarized in Table 3







TABLE 3







Reactivity of human or guinea pig anti-RBD2


antisera with synthetic peptides









Peptide ID No.
Synthetic
Reactive Titers










(SEQ ID NO:)
peptides
Human
Guinea pig





76
CVNFNFNGLTGTGVL
1/5
0/3


(SEQ ID NO:126)


 


77
FNGLTGTGVLTPSSK
1/5
0/3


(SEQ ID NO:127)


 


78
GTGVLTPSSKRFQPF
0/5
0/3


(SEQ ID NO:128)


 


79
TPSSKRFQPFQQFGR
0/5
0/3


(SEQ ID NO:129)


 


80
RFQPFQQFGRDVSDF
0/5
0/3


(SEQ ID NO:130)


 


81
QQFGRDVSDFTDSVR
1/5
0/3


(SEQ ID NO:131)


 


82
DVSDFTDSVRDPKTS
2/5
1/3


(SEQ ID NO:132)


 


83
TDSVRDPKTSEILDT
15
1/3


(SEQ ID NO:133)


 


84
DPKTSEILDISPCAF
0/5
0/3


(SEQ ID NO:134)


 


85
EILDISPCAFGGVSV
1/5
0/3


(SEQ ID NO:135)


 


86
SPCAFGGVSVITPGT
0/5
0/3


(SEQ ID NO:136)


 


87
GGVSVITPGTNASSE
0/5
0/3


(SEQ ID NO:137)


 


88
ITPGTNASSEVAVLY
5/5
3/3


(SEQ ID NO:138)


 


89
NASSEVAVLYQDVNC
5/5
3/3


(SEQ ID NO:139)


 


90
VAVLYQDVNCTDVST
4/5
1/3


(SEQ ID NO:140)


 


91
QDVNCTDVSTAIHAD
1/5
0/3


(SEQ ID NO:141)


 


RBD-55

5/5
3/3


(SEQ ID NO:26)









As shown in Table 3, most of the peptides successfully detected the presence of anti-S protein antibody in the samples.
EXAMPLE 9
Further studies were performed to determine whether the binding of S2-Fc to VERO E6 cells could be neutralized by S protein or its fragments.
Recombinant RBD2 was tested first. 104 of VERO E6 cells were incubated with 330 ng/mL of S2-Fc protein in the presence or absence of know amount of RBD2 protein solution. It was found that 1 μg of RBD2 significantly reduced the S2-Fc binding to VERO E6 cells.
The inhibition assays were repeated with 11 cocktails, each containing nine RBD2 fragment and covering (S28 to S115). More specifically, the VERO E6 cells were harvested and washed twice with a FACS staining/washing buffer. 2×105 cells were incubated with various peptides and then stained in a final volume of 100 ml with recombinant S-Fc protein (1 mg), S2-Fc protein (0.2-0.3 mg), or hIgG1 as isotype control for 30 minutes at 4° C. Cells were washed twice and stained with the RPE-conjugated anti-hIg Abs for 30 minutes at 4° C. After washing, cells were fixed with fixation buffer for 30 minutes at 4° C., and then the fluorescence was detected with FACS Calibur (Becton Dickinson). The results are summarized in Table 4 below. The inhibition level by RBD2 was designated as 100%.







TABLE 4







Inhibition S2-Fc/VERO E6 cell Binding by S Peptides









Percent of Inhibition Concentration



of Synthetic peptides (μg/mL)










Blocking agents
1
10
100





Negative control (SEQ ID NOs:)
0
0
0


Gp(28-35) (SEQ ID NOs: 78-85)
0
0
0


Gp(36-43) (SEQ ID NOs: 86-93)
0
0
0


Gp(44-51) (SEQ ID NOs: 94-101)
0
0
0


Gp(52-59) (SEQ ID NOs: 102-109)
0
0
0


Gp(60-67) (SEQ ID NOs: 110-117)
0
0
0


Gp(68-75) (SEQ ID NQs: 118-125)
0
0
0


Gp(76-83) (SEQ ID NOs: 126-133)
0
0
0


Gp(84-91) (SEQ ID NOs: 134-141)
0
 10%
30%


Gp(92-99) (SEQ ID NOs: 142-149)
0
0
0


Gp(100-107) (SEQ ID NOs: 150-157)
0
0
0


Gp(108-115) (SEQ ID NOs: 158-165)
0
0
0


RRBD2 (SEQ ID NO: 24)
100%
100%
NA









As shown in Table 4, the peptide cocktail containing S peptides 84 to 91 (group #8) strongly inhibited the binding between S2-Fc and VERO-6 cells by 30% as compared with those in the RBD2. These results indicate that the major B-cell epitopes of S2 were located within the region covering these 9 peptides, i.e., residues 540 to 600 of S protein.
To more clearly define the protective epitope(s) of the S2 fragment, individual peptides S84-91 were also tested. 104 of VERO E6 cells were incubated with 330 ng per mL of S2-Fc protein in the presence or absence of the peptides, respectively. The inhibitions of the binding of S-Fc to VERO E6 cells were determined in the same manner described above. The same experiment was repeated using a polypeptide containing with 50 amino acids covering S84 to S91 (“RBD-55” shown in Table 2 above). The results are summarized in Table 5 below.







TABLE 5







Inhibition Activity of S Synthetic Peptides against S2-Fc/VERO E6 cell


Binding









Percent of Inhibition Concentration



of Synthetic peptides (μg/mL)










Blocking agents
1
10
100













Negative control (SEQ ID NOs:)
0
0
0


Gp(76-83) (SEQ ID NOs: 126-133)
0
0
0


Gp(84-91) (SEQ ID NO: 134-141)
0
10
30


S84 (SEQ ID NO: 134)
0
0
0


S85 (SEQ ID NO: 135)
0
0
0


S86 (SEQ ID NO: 136)
0
0
10


S87 (SEQ ID NO: 137)
0
0
0


S88 (SEQ ID NO: 138)
0
0
0


S89 (SEQ ID NO: 139)
0
0
10


S90 (SEQ ID NO: 140)
0
0
0


S91 (SEQ ID NO: 141)
0
0
0


S86 + S87 (SEQ ID NOs: 136 and
0
20
40


137)


S86 + S88 (SEQ ID NOs: 136 and
0
0
0


138)


S86 + S89 (SEQ ID NOs: 136 and
0
20
40


139)


S86 + S90 (SEQ ID NOs: 136 and
0
0
0


140)


S86 + S91 (SEQ ID NOs: 136 and
0
0
0


141)


RBD-55 (SEQ ID NO: 26)
10
30
60


rRBD2 (SEQ ID NOs: 24)
100
100
Not test









As shown in Table 5, both S86 and S89 statistically significantly inhibited the S2-Fc/VERO cell binding. Furthermore, S86 and S87, or S86 and S89 exhibited synergetic effect and could inhibit 30% of S2-Fc/Vero cell binding. Each of S86 and S89 contains two cysteine residues on both termini, which could form a disulfide bridge and might lead to strong inhibition. RBD-55 inhibited the S2-FCNERO E6 cell binding more significantly than S86 or S89 peptide (60% inhibition vs 10% inhibition). These results indicate that RBD-55 could be used as an immunogen to induce protective antibodies against SARS CoV.
EXAMPLE 10
The above-described peptides were used to generate S peptide-specific antisera. Guinea pigs and rabbits were immunized with peptides cocktail (50 to 200 μg) emulsified with the Freund's complete adjuvant and injected intramuscularly. The animals were boosted with the same amount of peptide cocktails in the incomplete Freund's adjuvant at days 14 and 28. Antisera were collected on day 42 and tested by ELISAs and immunoblotting. Both rabbit and guinea pig antisera were shown to be monospecific for their respective immunizing peptides by the peptide-specific ELISAs. In addition, both guinea pig and rabbit antisera raised against S peptides reacted with SARS CoV on immunoblot analyses. Since most S peptides induced strong anti-peptide antibody responses in at least one animal species, they are appropriate immunogens to be included in immunogenic compositions, e.g., vaccines.
EXAMPLE 11
Infant ferrets were used to examine the protective activity of S-specific antisera against SARS CoV challenge as described by NIH (Yang et al., Nature (2004) 428:561-564.). Five-day old infant ferrates were inoculated subcutaneously (SC) on the dorsum with 0.15 mL of two different rabbit anti-S fragments. Pre-immune sera were used as negative controls. One day after this passive immunization, the infant ferrets were injected intraperitoneally (IP) with 4000 plaque-forming units (cfu) of SARS CoV Tor2 strain (0.1 ml) freshly grown and isolated from a Vero cell culture medium supplemented with cofactors and diluted in PBS containing 0.5 mM MgCl2 and 0.15 mM CaCl2. One day later, blood samples were collected via cardiac puncture under methoxyflurane anaesthesia and cultured in the Vero cell media. The number of virus per mL of blood was determined after 24 hours. The Student's t-test was used to analyze differences observed in the levels of viramia relative to controls. The results indicate that the antibodies protect against SARS CoV challenge
The protective ability of anti-RBD1 sera against SARS CoV infection was examined in the ferret model. It was that ferret passively immunized with guinea pig anti-RBD1 antisera were not more protective than pre-bleed serum control.
EXAMPLE 12
Little is known about the cellular immune response to SARS CoV and its role in protecting against SARS CoV infection. To examine the cellular response elicited by SARS CoV, T-cell lines' proliferative responses to S peptides were determined by conventional cytokine assays as described below.
S-specific T-cell lines were generated. BALB/c (H-2d) mice (Charles River Animal Farm, Montreal, Canada) were primed subcutaneously with 20 μg of recombinant S adsorbed to 1.5 mg of aluminium phosphate (alum) in presence of 100 μg of CpG. The mice were boosted twice with the same dose of immunogen at 3-week intervals.
Ten days after the final boost, the spleen of each immunized mouse was removed. Splenocytes were isolated and cultured in 200 μL of RPMI 1640 medium (Flow Lab) at 5.75×105 cells per well of a microtiter plate. The medium was supplemented with 10% heat-inactivated fetal calf serum (Gibson), 2 mM L-glutamine, 100 U/mL) penicillin, and 5×0.10−5 M 2-mercaptoethanol and contained varying concentrations (1, 10 and 100 μg per mL) of individual S peptides. The cultures were kept in a humidified incubator in the presence of 5% CO2/air. Triplicate cultures were performed for each concentration of each peptide. Five days later, 150 μL of 10% rat concanavalin A culture supernatant diluted in the culture medium was added to the microtiter plate wells. The supernatant contained Interleukin-2 (IL-2), which expand peptide-specific T-cells.
Six days later, 150 μL of the supernatant were removed from each microculture, and 150 μL of a fresh IL-2 containing culture supernatant added to further expand and maintain the viability of the peptide-specific T-cells. After another 6 day-incubation, the cells were washed with 200 μL culture medium for three times. Each set of cultures were then stimulated with a peptide at concentrations of 1, 10, and 100 μg/mL, respectively in the presence of 2×0.105 irradiated (1,500 rad) BALB/c spleen cells in a final volume of 200 μL culture medium. Sixty microliters of the supernatant were then removed from each triplicate culture and pooled. All supernatants were then assayed for IL-2, IL-4, and Interferon-gamma (IFN-gamma) using murine IL-2 and IL-4 ELISA kits (Endogen Inc, MA, U.S.A.) and a mouse IFN-gamma ELISA kit (Genzyme Corporation. MA, U.S.A.). Test culture supernatants were assayed at 1 in 5 dilution according to the manufacturers' instructions.
The results indicated that peptides corresponding to residues 120-134, 649-688, and 699-713 elicited proliferative responses and the release of specific cytokines. Because of this strong ability to induce cellular immune response, these immunodominant T-cell epitopes can be used as carriers for pneumococcal polysaccharides and/or S B-cell epitopes to enhance the immunogenicity. The Th1 cell epitopes identified above can be used in SARS CoV vaccine formulations to induce SARS-specific cellular immune responses.
EXAMPLE 13
In this example, murine anti-S monoclonal antibodies were generated. BALB/c mice were immunized intraperitoneally with 20 to 50 μg of RBD2 emulsified in the Freund's complete adjuvant. Two weeks later, the mice were injected with the same amount of immunogen in the incomplete Freund's adjuvant. The anti-S titers were examined. Positive mice were selected for making hybridomas by standard cell fusion techniques. Three days before the fusion, the mice were boosted again with the same amount of immunogen in the incomplete Freund's adjuvant. Hybridomas were produced by fusion of splenic lymphocytes from immunized mice with non-secreting Sp2/0 myeloma cells in the manner described in Hamel et al. 1987, J. Med. Microbiol. 23:163-170. S-specific hybridomas were cloned by sequential limiting dilutions and screened for anti-S monoclonal antibody production. Eight S-specific hybridoma cell lines were identified, expanded, and frozen in liquid nitrogen by standard techniques.
EXAMPLE 14
The mechanism of SARS CoV infection is unclear although it was reported that infection took place through enteric route, respiratory tract, and skin. As discussed above, S1-Fc and S2-Fc, but not S3-Fc, bind to VERO cells. To test whether S3-Fc binds to any other cells, a panel of cell lines were tested. About 1×104 cells/mL were incubated with 0.1, 0.3, and 1 μg of S3-Fc or the same amount of S1-Fc or S2-Fc in a volume of 1 mL for 2 hours at room temperature. The cells were washed in PBS with 0.5% BSA and 0.1% NaN3, incubated with FITC-labeled goat anti-human IgG Fc (Sigma), and analyzed by flow cytometry.
It was unexpected that S3-Fc bound strongly to NIH 3T3 cells but not to Jarket cells. S3-Fc showed strong binding to NIH 3T3 cells even at a concentration as low as 0.1 μg/mL. In contrast, S1-Fc did not bind to NIH3T3 cells even at 10 μg/mL, and S2-Fc showed some binding to NIH 3T3 cell at 1 μg/mL. These results indicate that S3-Fc had specificity toward receptors in NIH 3T3 cells.
It was also unexpected that S protein also binds to HeLa, BHK-21, and COS-7 cells. Three separated receptor-binding domains of S protein were identified: (1) the low affinity mapped to the N-terminal 333 residues, (2) a intermediate affinity receptor-binding domain (with 1 μM avidity) mapped to residues 334 to 666, and (3) a high affinity domain within residues 667 to 999. Beside VERO E6 cells, all these cell lines had not been reported before to be the hosts for SARS CoV replication. This explained why SARS CoV could infect patient via skin contact with infected solutions.
OTHER EMBODIMENTS
All of the features disclosed in this specification may be combined in any combination. Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features.
From the above description, one skilled in the art can easily ascertain the essential characteristics of the present invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, other embodiments are also within the scope of the following claims.

## Claims

1. An isolated polypeptide consisting of the sequence selected from the group consisting of SEQ ID NO: 24, 26, 28 and 85-95.

2. The polypeptide of claim 1, wherein the sequence is SEQ ID NO: 24 or 26.

3. An isolated glycoprotein consisting of the polypeptide of claim 1 and a polysaccharide.

4. The glycoprotein of claim 3, wherein the polysaccharide is from S. pneumococcal.

5. A fusion protein comprising a SARS CoV spike protein fragment and a heterologous polypeptide wherein the spike protein fragment consists of a polypeptide of claim 1.

6. The fusion protein of claim 5, wherein the heterologous polypeptide contains an Fc portion of an immunoglobin.

7. The fusion protein of claim 6, wherein the immunoglobin is IgG.

8. The fusion protein of claim 7, wherein the immunoglobin is IgG1.

9. The fusion protein of claim 8, wherein the immunoglobin is human IgG1.

10. The fusion protein of claim 5, wherein the heterologous polypeptide contains a surface portion of a protein of a pathogen.

11. The fusion protein of claim 10, wherein the surface portion of a protein contains hemaglutinin or neuramidase of an influenza virus.

12. A composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

13. A composition comprising the fusion protein of claim 5 and a pharmaceutically acceptable carrier.